SG
DNA icon

StoneX Group’s Ginkgo Bioworks DNA Stock Holding History

StoneX Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-319
Closed -$14.8K – 688
2024
Q1 		$14.8K Buy
+319
New +$16.5K ﹤0.01% 574
2023
Q4 		– Sell
-299
Closed -$21.7K – 645
2023
Q3 		$21.7K Buy
+299
New +$23.9K ﹤0.01% 585

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

StoneX Group's DNA Position: Q2 2024 in Review

StoneX Group sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 319 shares — an estimated $14.8K sold.

StoneX Group first reported a position in DNA in Q3 2023 and held it in 2 quarters. The position peaked at $21.7K in Q3 2023. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

  • StoneX Group reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
  • StoneX Group sold 319 Ginkgo Bioworks shares in Q2 2024, an estimated $14.8K.
  • StoneX Group first reported a position in Ginkgo Bioworks in Q3 2023 and held it in 2 quarters.
  • StoneX Group's Ginkgo Bioworks position peaked at $21.7K in Q3 2023.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on StoneX Group's 13F filing for Q2 2024, filed 7 Aug 2024.